Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Operating expenses
Research and development	$ 26,877,000	$ 6,398,000
Acquired in-process research and development	174,310,000	4,395,000
General and administrative	9,685,000	10,499,000
Restructuring costs	0	968,000
Total operating expenses	210,872,000	22,260,000
Loss from operations	(210,872,000)	(22,260,000)
Other income (expense), net
Interest income, net	1,167,000	844,000
Foreign exchange transaction gain (loss), net	(84,000)	18,000
Total other income, net	1,083,000	862,000
Loss before income tax expense	(209,789,000)	(21,398,000)
Income tax expense	(50,000)	(41,000)
Net loss	$ (209,839,000)	$ (21,439,000)
Net loss per share, basic, common stock	$ 3.98	$ (18.53)
Net loss per share, diluted, common stock	$ 3.98	$ (18.53)
Weighted-average number of shares used in computing net loss per common share, basic	1,363,005	1,157,149
Weighted-average number of shares used in computing net loss per common share, diluted	1,363,005	1,157,149
Other comprehensive income (loss), net of tax
Currency translation gain (loss)	$ 705,000	$ (283,000)
Other comprehensive income (loss), net of tax	705,000	(283,000)
Total comprehensive loss	(209,134,000)	(21,722,000)
Series B Non-Voting Convertible Preferred Stock
Other income (expense), net
Net loss	$ (55,529,000)	$ 0
Net loss per share, basic, common stock	$ (23,816)	$ 0
Net loss per share, diluted, common stock	$ (23,816)	$ 0
Weighted-average number of shares used in computing net loss per common share, basic	2,332	0
Weighted-average number of shares used in computing net loss per common share, diluted	2,332	0
Series C Non-Voting Convertible Preferred Stock
Other income (expense), net
Net loss	$ (148,890,000)	$ 0
Net loss per share, basic, common stock	$ (23,816)	$ 0
Net loss per share, diluted, common stock	$ (23,816)	$ 0
Weighted-average number of shares used in computing net loss per common share, basic	6,252	0
Weighted-average number of shares used in computing net loss per common share, diluted	6,252	0
Common Stock
Other income (expense), net
Net loss	$ (5,420,000)	$ (21,439,000)
Net loss per share, basic, common stock	$ (3.98)	$ (18.53)
Net loss per share, diluted, common stock	$ (3.98)	$ (18.53)
Weighted-average number of shares used in computing net loss per common share, basic	1,363,005	1,157,149
Weighted-average number of shares used in computing net loss per common share, diluted	1,363,005	1,157,149

Damora Therapeutics, Inc. 10-K